Nova Rodriguez, a medical assistant at UC Berkeley University Health Services, prepares a dose of the Moderna COVID-19 vaccine before giving it to other University Health Services employees at the Tang Center near UC Berkeley in Berkeley, California.
Jessica Christian | San Francisco Chronicle | Hearst Newspapers via Getty Images
Moderna said Monday it was speeding up work on a Covid-19 booster shot to protect against the recently discovered variant in South Africa.
The researchers said the current coronavirus vaccine appears to work against the two highly communicable strains in the UK and South Africa, although it may be less effective against the latter.
The two-dose vaccine produced an antibody response against several variants, including B.1.1.7 and B.1.351, which were first identified in the UK and South Africa, respectively. This was the result of a Moderna study carried out in collaboration with the National Institute of Allergy and Infectious Diseases. The study has not yet been peer-reviewed.
The vaccine produced a weaker immune response against the South African strain, but the antibodies remained above levels expected to protect against the virus, company B.1,351 strains said.
“Out of caution and taking advantage of the flexibility of our mRNA platform, we are bringing an ambitious variant booster candidate against the variant first identified in the Republic of South Africa to the clinic in order to determine whether it is more effective to increase the titre against it.” these and possibly future variants, “said Stephane Bancel, CEO of Moderna, in a statement.
On Thursday, White House health advisor Dr. Anthony Fauci, new data showed that the Covid-19 vaccines currently on the market may not be as effective against new, more contagious strains of the coronavirus. Some early insights published on the preprint server bioRxiv points out that the South African variant can evade the antibodies of some coronavirus treatments.
The Food and Drug Administration approved Moderna’s vaccine for people aged 18 and over in December.
Moderna’s vaccine, like Pfizer’s, uses messenger RNA or mRNA technology. It’s a new approach to vaccines that uses genetic material to trigger an immune response. Late-stage clinical trial data released in November shows that Moderna Covid’s vaccine is more than 94% effective at preventing, safe and appearing to ward off serious illness. For maximum effectiveness, the vaccine requires two doses four weeks apart.
This is a developing story. Please try again.
– CNBCs Noah Higgins-Dunn contributed to this report.